pirtobrutinib

Pirtobrutinib is a small molecule, non-covalent (reversible) inhibitor of Bruton's tyrosine kinase (BTK), developed for the treatment of B-cell malignancies. It is indicated for adults with relapsed or refractory mantle cell lymphoma (MCL) after at least two prior lines of therapy including a BTK inhibitor, and for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adults who have received at least two prior therapies including a BTK inhibitor and a BCL-2 inhibitor. Pirtobrutinib works by selectively binding to both wild-type and C481-mutated forms of BTK, thereby inhibiting signaling pathways essential for malignant B-cell proliferation and survival. Unlike covalent BTK inhibitors such as ibrutinib, pirtobrutinib binds reversibly to the ATP-binding site on BTK, maintaining efficacy even in cases with resistance mutations at C481. The drug was developed by Loxo Oncology and is marketed under the brand name Jaypirca by Lilly USA[3][5][6][7].

Brand names

Jaypirca

Other names

pirtobrutinib